智通财经APP讯，精优药业(00858)公布，于2026年3月27日，订约方订立不具法律约束力的谅解备忘录，据此，公司拟向潜在买方Marvel Nice Limited出售全部可换股债券及╱或将公司于第四份修订契据项下的所有权益及利益转让予潜在买方。
标的事项为(i)由星太链发行、经日期为 2023年7月 12日的第三份经修订及重述文据构成及本金总额为7.15亿港元的可换股债券，包括(a)其所有应计利息;(b)其所有到期及应收款项;及(c)所附带将其转换为星太链缴足普通股的所有换股权;及(ii)公司于第四份修订契据项下 的所有权益及利益(其中若干条件包括须经联交所及公司与星太链各自的股东批准)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.